A Single Arm Study of SNX-5422 in Subjects With TP53 Null Cancers
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2016
At a glance
- Drugs SNX 5422 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- Sponsors Esanex
- 03 Nov 2016 Status changed from recruiting to discontinued due to very slow recruitment.
- 22 Mar 2016 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017, according to ClinicalTrials.gov record.
- 22 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.